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Abstract
Background: ACE Inhibitors (ACE-I) and Angiotensin-Receptor Antagonists (ARAs) are commonly prescribed but can cause
acute kidney injury (AKI) during intercurrent illness. Rates of hospitalization with AKI are increasing. We aimed to determine
whether hospital AKI admission rates are associated with increased ACE-I/ARA prescribing.
Methods and Findings: English NHS prescribing data for ACE-I/ARA prescriptions were matched at the level of the general
practice to numbers of hospital admissions with a primary diagnosis of AKI. Numbers of prescriptions were weighted for the
demographic characteristics of general practices by expressing prescribing as rates where the denominator is Age, Sex, and
Temporary Resident Originated Prescribing Units (ASTRO-PUs). We performed a mixed-effect Poisson regression to model
the number of admissions for AKI occurring in each practice for each of 4 years from 1/4/2007. From 2007/8-2010/11,
crude AKI admission rates increased from 0.38 to 0.57 per 1000 patients (51.6% increase), and national annual ACE-I/ARA
prescribing rates increased by 0.032 from 0.202 to 0.234 (15.8% increase). There was strong evidence (p,0.001) that
increases in practice-level prescribing of ACE-I/ARA over the study period were associated with an increase in AKI admission
rates. The increase in prescribing seen in a typical practice corresponded to an increase in admissions of approximately 5.1%
(rate ratio = 1.051 for a 0.03 per ASTRO-PU increase in annual prescribing rate, 95%CI 1.047-1.055). Using the regression
model we predict that 1,636 (95%CI 1,540-1,780) AKI admissions would have been avoided if prescribing rates were at the
2007/8 level, equivalent to 14.8% of the total increase in AKI admissions.
Conclusion: In this ecological analysis, up to 15% of the increase in AKI admissions in England over a 4-year time period is
potentially attributable to increased prescribing of ACE-I and ARAs. However, these findings are limited by the lack of
patient level data such as indication for prescribing and patient characteristics.
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Introduction
Acute kidney injury (AKI) is a common problem implicated in a
substantial proportion of hospital admissions and the incidence is
increasing [1–3]. It is associated with a marked increase in
mortality [1] and also leads to prolonged hospital stay, increased
secondary care costs [4] and possibly accelerated decline in long-
term kidney function [5].
AKI has many and often multifactorial aetiologies [6].
However, an important cause is the use of ACE inhibitor and
Angiotensin-II Receptor Antagonists (ARA) drugs which are
associated with AKI in a range of settings, particularly during
acute hypovolaemic illness [7–13]. The increased risk of AKI
among patients taking these medications has been recognised by
the UK National Institute for Health and Clinical Excellence
(NICE) and the international organisation Kidney Disease:
Improving Global Outcomes (KDIGO), both of which recom-
mend that patients with chronic kidney disease (CKD) should stop
taking them if they become acutely unwell [14,15].
There are many evidence based indications for use of ACE
inhibitors and ARAs and national guidelines recommend treat-
ment with them for a number of chronic conditions including
hypertension, chronic kidney disease with proteinuria, and heart
failure with left ventricular dysfunction. The result is that these
medicines are the second most commonly prescribed in English
primary care, accounting for 6% of all prescriptions [16]. Due to
increasing prevalence of chronic comorbidities in older people
they are commonly used in the elderly: in Belgium, 7.3% of the
population were treated with long-term ACE inhibitors or ARAs
and this rose to 36% for people aged 80 years or more [17].
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However, despite their frequent use, it is not known to what
extent increasing use of these medications has contributed to the
increasing incidence of AKI on a population level. This is in part
because observational studies on this topic are confounded by
indication. The conditions for which ACE inhibitors and ARAs
are indicated are themselves associated with increased risk of AKI.
Therefore increasing incidence of AKI may reflect increasing
prevalence of comorbidities, independently of medications used.
We hypothesised that if these medications were playing a causal
role, changes in prescribing would be associated with changes in
hospital admission with AKI within general practices. We
therefore conducted a longitudinal ecological analysis using
routinely-collected national hospital administrative data to deter-
mine whether hospital admission rates with AKI in England are
associated with increased prescribing of ACE inhibitor and ARA
therapy.
Methods
Data sources
All data used in this study relates to the period 1st April 2007 to
31st March 2011. We used prescribing data from the English
National Health Service (NHS) Prescription Services’ Prescribing
Database (ePACT) [18]. This provides data for each English
general practice for the total number of prescriptions that were
prescribed and subsequently dispensed, although information
about the quantity of medication provided is not captured.
We obtained the numbers of ACE inhibitor (British National
Formulary sub-section 2.5.5.1) [19] and ARA prescriptions (British
National Formulary sub-section 2.5.5.2) from all general practices
in England during the study period. The number of prescriptions
for ACE inhibitors and ARAs issued by a general practice will be
related to the age and sex demographic of the practice population.
Therefore we controlled for differences in general practice
populations by expressing prescribing as rates where the denom-
inator is Age, Sex, and Temporary Resident Originated Prescrib-
ing Units (ASTRO-PUs) [20]. Because prescribing is generally
higher in women and older people, ASTRO-PUs provide a
nationally accepted way of weighting prescribing for the age and
sex characteristics of the population of a general practice, and thus
facilitating the comparison of prescribing between practices. The
numbers of ASTRO-PUs for each general practice are updated
regularly and a revision to the values of was carried out in April
2008. Therefore, for consistency we used the pre-2008 weightings,
devised in 2001, throughout the entire study period. In this study,
on average, each person is represented by 4.3 ASTRO-PUs.
We obtained the number of hospital admissions with AKI using
data from Hospital Episode Statistics (HES) [21]. HES contains
administrative details including diagnostic information on the vast
majority of admissions to hospitals in England, coded using the
tenth edition of the International Statistical Classification of
Diseases and Related Health Problems (ICD-10) [22]. Within
HES, each admission is comprised of one or more episodes, with
each episode reflecting care by a responsible clinician in a
particular hospital ward or department. It is common practice to
group episodes occurring close to each other as relating to a
continuous period of care (an admission) even if there are small
gaps between episodes. We therefore treated episodes occurring
within three days of one another as a single admission even if the
episodes were recorded under separate admissions (as may happen
if patients were transferred between hospitals). The robustness of
this approach is examined in a sensitivity analysis (see below).
Each episode records a primary diagnosis (the main condition
treated or investigated during this episode) and up to 19 additional
secondary diagnoses. For the main analysis defining an AKI
admission we required code N17 (acute renal failure) to be present
as the primary diagnosis for any episode within seven days of the
date of admission. Since ICD-10 was introduced, the term AKI
has largely replaced acute renal failure in clinical use but this has
not yet been amended for coding purposes. We have previously
examined the positive predictive value of code N17 in HES data
for the KDIGO definition of AKI and found that for both 2005
and 2010 it was accurate for 95% of cases [23].
Statistical analysis
We matched the NHS prescribing data to numbers of hospital
admissions for AKI at general practice level, aggregated to four
one-year periods starting on 1st April 2007. A mixed effect Poisson
regression was performed to model the number of admissions for
AKI occurring in each practice in each year. Within the model we
included prescribing rates (continuous) and year (categorical) as
fixed effects variables, together with a random intercept term for
general practice. The purpose of the random intercept is to cast
the effect of prescribing rates as a within practice, rather than
between practice, comparison. In other words the resulting rate
ratios can be considered to represent the changes in admission rate
when the other variables change for a single practice. The number
of person-years at risk was based on the practice population sizes
obtained from annual figures recorded as part of the English
primary care pay-for-performance scheme, the Quality and
Outcomes Framework [24]. A mixed model such as this allows
the use of data from general practices where observations are not
present for every year (primarily due to general practices closing,
opening, and merging during the time period under investigation).
To minimize the influence of unusually high prescribing practices
on our findings, we excluded general practices with prescribing
rates greater than 0.5 ACE inhibitor and ARA prescription per
ASTRO-PU.
The relationship between hospital admissions and prescribing
was quantified using the change in admissions for an average
annual increase in prescribing rate. We also used the model to
estimate the number of admissions that would have been avoided
in 2010/11 had the prescribing rate for each practice been the
same as it had been in 2007/8. In the case of general practices
which did not exist in 2007/8, the mean 2007/8 prescribing rate
was used in this calculation. Confidence intervals on the number of
admissions avoided were calculated using a bootstrap with 100
samples clustered by general practice.
Sensitivity analyses
To ensure the robustness of our findings, we performed a
number of sensitivity analyses.
Over the time course of this study there have been substantial
attempts to raise recognition of AKI in hospital patients, as well as
altered use of coding to define hospital remuneration. Therefore it
is possible that an individual with AKI has a greater probability of
this condition being diagnosed and recorded towards the end of
the study period, and this may explain to some extent a change in
incidence of AKI defined by HES coding. We examined whether
our results could be explained by improvements in the thorough-
ness of clinical coding over time by adjusting for the number of
secondary diagnoses recorded (the ‘‘coding depth’’). Similarly, we
examined whether including admissions defined by ICD-10 code
N19 (unspecified kidney failure) affected our findings. We
examined the effect of restricting the maximum length of included
episodes to less than two months, based on the premise that
patients may develop AKI during a prolonged admission, despite
there being a different primary clinical reason for the admission.
Prescribing and Acute Kidney Injury
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Finally, we looked at the effect of altering the overlap of three days
that we used to identify a single continuous admission. Further
details are given in table S2.
Results
The nationwide changes over time in ACE inhibitor and ARA
prescribing and AKI admissions are shown in Table 1 and Figure
1. National annual prescribing rates increased by 0.032 from 0.202
to 0.234 prescriptions per ASTRO-PU over the four years studied
(16% increase). Hospital admission rates coded to have AKI in the
primary coding position also increased from 0.38 to 0.57 per 1000
patients over the same period, an increase of 52%.
The number of general practices included in our analysis (i.e.
those with both admission and prescribing data, and an ACE
inhibitor and ARA prescribing rate less than 0.5 prescriptions per
ASTRO-PU) fell from 8039 in 2007/8 to 7959 in 2010/11,
although the total population increased from 53.3 to 54.5 million.
In any one year, a maximum of 33 general practices (0.4%) were
excluded due to the ACE inhibitor and ARA prescribing rate
being greater than 0.5 prescriptions per ASTRO-PU.
There were substantial variations in both ACE inhibitor and
ARA prescribing rates, and AKI admission rates between general
practices (Table S1). For example in 2007/8 the median practice
level ACE inhibitor and ARA prescribing rate was 0.20
prescriptions per ASTRO-PU with an interquartile range of
0.15 to 0.25. For AKI admissions the median value was 0.33
admissions per 1000 patients with an interquartile range of 0.13 to
0.54. Similarly the increase in prescribing rate varied considerably
between general practices. The median increase was 0.030
prescriptions per ASTRO-PU over the four years studied with
an interquartile range of 0.015 to 0.048. The corresponding
median increase in number of prescriptions was 882 (IQR 411 to
1616). However, 8.9% of general practices had lower prescribing
rates in 2010/11 than in 2007/8.
Results from the Poisson regression model are detailed in Table
2. This shows clear evidence of an increase in AKI admission rates
over time (p,0.001), with the average admissions rate 44% higher
in 2010/11 than in 2007/8. There is additional strong evidence
(p,0.001) that increased ACE inhibitor and ARA general practice
prescribing rates were independently associated with increased
Figure 1. National admission rates of acute kidney injury and prescriptions of ACE Inhibitors and Angiotensin Receptor
Antagonists in England between 2007 and 2011. Striped (left) bars represent hospital admission rates; Black (right) bars represent ACE inhibitor
and Angiotensin Receptor Blocker prescription rates.
doi:10.1371/journal.pone.0078465.g001
Table 1. National figures for number of general practices,
total prescribing and total hospital admissions.
2007/8 2008/9 2009/10 2010/11
Number of general practices 8039 8027 8024 7959
Population (Millions) 53.25 53.68 54.30 54.45
Number of prescriptions
(Millions)
46.31 50.19 53.13 55.50
Number of ASTRO-PUs
(Millions)
229.15 231.95 235.13 237.52
Prescribing rate
(per ASTRO-PU)
0.20 0.22 0.23 0.23
Number of admissions 20118 24314 28555 31180
Admission rate (per 1000
people)
0.38 0.45 0.53 0.57
ASTRO-PU - age, sex and temporary resident adjusted prescribing unit
doi:10.1371/journal.pone.0078465.t001
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AKI admission rates, even after the adjustment for the underlying
trend over time.
To quantify this it is helpful to consider the effect associated
with the median general practice increase in prescribing over the
study period, i.e. 0.030 prescriptions per ASTRO-PU. For such a
within practice increase there is on average a 5.1% increase in the
hospital admission rate for AKI (rate ratio 1.051, 95% CI 1.047 to
1.055) after adjustment for national increases over time. Using the
regression model we predict that 1,636 (95% CI 1,540-1,780) AKI
admissions would have been avoided if prescribing rates were at
the 2007/8 level. This is equivalent to 14.8% of the total increase
in AKI admissions (11,062).
The results of the sensitivity analyses are summarised in table
S2. Whilst there are some differences in the effect of year which
may reflect changes in coding practice over time, the estimates of
the effect of prescribing in all models is very similar to that of the
primary analysis indicating that the main finding is robust to our
operational definition of an AKI admission.
Discussion
Over the four-year period of this study, ACE inhibitor and ARA
prescribing increased by approximately 16%, and hospital
admissions with AKI by just over a half. Our analyses provide
strong evidence that, at the level of the general practice, the
increase in prescribing is associated with the increase in
hospitalisation, and indeed may account for almost 15% of the
total increase in AKI admissions.
These findings are consistent with other studies which have
demonstrated an increasing incidence of AKI and evidence that
AKI can result from treatment with ACE inhibitors and ARAs,
usually in the presence of an intercurrent illness. However, it is the
first study to quantify the extent to which the changing incidence
of AKI may be due to these medications. Studies to examine the
association between treatment with ACE inhibitors and ARAs and
AKI are difficult since both the drugs and the reason for
prescribing them are risk factors for AKI. Patients prescribed
and not prescribed the drugs differ in a range of characteristics
which are not easily overcome by matching. Previous studies on
this topic have tried to overcome this problem through studying
interactions between medications [7,25] or by attempting to
control for the indications for prescribing using methods such as
propensity scoring or multivariable logistic regression [10,11,13].
This is the first ecological study to examine this topic and as such
has important strengths including the use of a large, real-world
dataset. Because the large majority of England’s population use the
state-funded NHS, our study will have captured nearly all relevant
prescribing and acute hospital admissions. Our longitudinal study
design, incorporating a random effect for practice, also allows us to
examine within-practice changes. This overcomes some of the
usual problems of ecological analyses, including allowing us to
adjust for underlying upward trends in AKI coding. These results
add support to the need for carefully designed studies using
individual level patient data to examine this issue in more depth.
However, there are also limitations to the analysis. The findings
of ecological studies may not reflect individual-level associations
and several other factors could explain or contribute to our
findings. It is likely that some of the observed increase in hospital
admissions with AKI is explained by a higher proportion of cases
of AKI being correctly coded due to greater clinical recognition of
cases, change in hospital remuneration policies or both. However,
this is unlikely to fully explain the associations we have observed
since it would not be expected that better hospital coding is
associated with changes in prescribing at individual practices. In
addition, the findings of the sensitivity analyses examining coding
depth provide very similar findings to the main analysis. Our use
of hospital administrative coding for AKI is not an ideal measure
of incident cases of AKI. Studies of the accuracy of coding for AKI
compared to biochemical definitions show that coding has a low
sensitivity [26] and can by definition only capture more serious,
hospitalized cases. However, we have previously shown that this
code, where present, is accurate.
Secondly, the results may also be explained in part by ageing of
the population which leads to both increased prescribing of ACE
inhibitors and ARAs, and increased risk of AKI. However, our
prescribing data is adjusted for the changing age profile of
individual general practices. Alternately, an increase in prevalence
of comorbidities such as heart failure and chronic kidney disease,
again associated with AKI and with prescribing of ACE inhibitors
and ARAs, might also be expected to explain some of the
association. However, it is likely that any increase in prevalence
will be small over the four-year period in question. No accurate
data exists to estimate prevalence of these conditions at the level of
general practices so we were not able to adjust for them.
Finally, increased use of ACE inhibitors and ARAs may be a
marker for increased use of other drugs causally associated with
AKI such as diuretics and non-steroidal anti-inflammatory drugs
(NSAIDs). Lack of individual patient level data meant that it was
not possible to adjust for use of these medications. Nonetheless,
there are strong reasons to consider a causal explanation for our
findings and if an association between prescribing and admissions
at an individual level exists, due to multiple sources of
measurement error our practice-level analysis is likely to have
underestimated the strength of this association. While the effect
Table 2. Association between ACE inhibitor and ARA prescribing and hospital admission with AKI: results from Poisson regression.
Exposure Rate ratio{ (95% confidence interval)
ACE inhibitor and ARA prescribing* 1.051 (1.047, 1.055)
Year 2007/8 Ref
2008/9 1.172 (1.150, 1.194)
2009/10 1.341 (1.317, 1.366)
2010/11 1.442 (1.416, 1.469)
*Rate ratio is expressed as change in AKI admission rate for the median general practice increase in prescribing over the study period (0.030 units per ASTRO-PU).
ASTRO-PU - age, sex and temporary resident adjusted prescribing unit.
{P,0.001 for all variables.
doi:10.1371/journal.pone.0078465.t002
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size is small this does equate to a substantial number of potentially
preventable cases of AKI nationally. It is important to note that
the model does not estimate the proportion of AKI admissions
attributable to ACE inhibitors and ARAs but the increase
attributable to the increase in prescribing over this time period.
This study covers a time period when use of ACE inhibitors and
ARAs were well established, and the increase in prescribing
modest. Larger increases in prescribing in the past, associated with
the issuing of relevant clinical guidance, may have resulted in a
considerably higher proportion of AKI admissions being attribut-
able to these treatments.
The relationship between prescribing of ACE inhibitors and
ARAs and AKI is important. There is a substantial body of
evidence for the benefits of these drugs for a range of common
chronic conditions. In the UK, NICE guidelines advise treatment
with them for hypertension, heart failure, ischaemic heart disease
and proteinuric chronic kidney disease, including diabetes with
minimal proteinuria. We face an ageing population with an
increasing burden of multimorbidity, so prescribing of these agents
is likely to increase further [27]. Quantification of the benefits of
these drugs and subsequent prescribing guidance are determined
from randomised clinical trials conducted in select populations
with close monitoring. In general clinical use, medications may be
used in populations different from that in which trials were
conducted and with less frequent patient safety checks [28].
Therefore, adverse effects may be more common in routine
clinical practice than in trials and the risk-benefit ratio may be
wrongly estimated. In light of this, it is important to investigate this
topic more fully in order to improve our understanding of the
factors associated with AKI in association with these medications,
in order to better risk stratify patients receiving them and to
develop evidence-based interventions to prevent this serious
complication.
In addition, the evidence regarding drug-associated AKI is
predominantly related to high-income countries. However,
treatment with ACE inhibitors is recommended by the World
Health Organization to prevent onset and delay progression of
CKD in low-resource settings [29]. The risk of AKI in low income
countries where infectious illness and volume depletion are
common is substantial and in the absence of treatment facilities
outcomes may be poor [30]. It is therefore vital to ensure that as
use of these drugs spreads to other regions, the risk: benefit ratio is
reevaluated.
Conclusion
In England, increased prescribing of ACE inhibitors and ARAs
may explain 15% of increased hospital admissions with AKI
between 2007 and 2011. Better understanding of individual level
risk factors for AKI associated with ACE inhibitors and ARAs are
needed to reduce the potential harms associated with these
important and commonly prescribed medications. This ecological
analysis demonstrates that the national increases in prescribing
may be a powerful driver of increased AKI incidence, and throws
uncertainty on the balance of benefits and risks associated with use
of these drugs.
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